Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Information for Advertisers
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Editor Picks
    • Blogging Stroke
    • AHA/ASA Guidelines and Statements
    • ISC and Nursing Symposium Abstracts
    • Progress and Innovation Award Recipients
    • Acknowledgment of Reviewers
    • Stroke in Women
    • Outstanding Reviewers 2017
  • Resources
    • Online Submission/Peer Review
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • → Tips for Submission
    • → Links and Forms
    • → Revised Manuscripts
    • Costs to Authors
    • Journal Policies
    • Wolters Kluwer Author Services
    • Early Career Resources
    • Stroke CME
    • Webinar Series
    • Permissions and Rights Q&A
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Stroke

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Information for Advertisers
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Editor Picks
    • Blogging Stroke
    • AHA/ASA Guidelines and Statements
    • ISC and Nursing Symposium Abstracts
    • Progress and Innovation Award Recipients
    • Acknowledgment of Reviewers
    • Stroke in Women
    • Outstanding Reviewers 2017
  • Resources
    • Online Submission/Peer Review
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • → Tips for Submission
    • → Links and Forms
    • → Revised Manuscripts
    • Costs to Authors
    • Journal Policies
    • Wolters Kluwer Author Services
    • Early Career Resources
    • Stroke CME
    • Webinar Series
    • Permissions and Rights Q&A
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Cochrane Corner

Hemostatic Drug Therapies for Acute, Nontraumatic Intracerebral Hemorrhage

Rustam Al-Shahi, Hong You
Download PDF
https://doi.org/10.1161/01.STR.0000251797.86897.a3
Stroke. 2007;38:204-205
Originally published December 22, 2006
Rustam Al-Shahi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong You
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
Loading
  • acute cerebral hemorrhage
  • intracerebral hemorrhage
  • emergency treatment of stroke
  • other stroke treatment, medical

Section Editor: Graeme J. Hankey MD, FRCP

Because nontraumatic intracerebral hemorrhage (ICH) volume strongly influences its outcome and a third of ICHs enlarge by a third within 24 hours of onset, hemostatic drug therapy given very soon after ICH onset might improve outcome.

Objective

We sought to determine the clinical effectiveness and safety of hemostatic drug therapies for acute nontraumatic ICH in randomized controlled trials (RCTs).

Search Strategy

In August 2005 we searched the Cochrane Stroke Group Trials Register, the Cochrane Central Register of Controlled Trials, MEDLINE from 1966 and EMBASE from 1980. We also scanned bibliographies of relevant articles, searched international registers of clinical trials and research, and contacted authors and pharmaceutical companies.

Selection Criteria

We sought randomized controlled trials of any hemostatic drug therapy for acute nontraumatic ICH, compared against placebo or open control, with relevant clinical outcome measures.

Data Collection and Analysis

Two review authors (R.A.-S., H.Y.) independently applied the inclusion criteria, reviewed the relevant studies, and extracted data from them.

Main Results

We found 4 phase II RCTs, involving adults aged 18 years or over, within 4 hours of nontraumatic ICH. One hundred and sixteen study participants received placebo and 373 received hemostatic drugs (2 received ε-aminocaproic acid and 371 received recombinant activated factor VII [rFVIIa]).

Hemostatic drugs reduced the relative risk of death within 90 days of nontraumatic ICH (risk reduction [RR] 0.67; 95% CI, 0.46 to 0.97, random effects; Figure). Specifically, rFVIIa appeared to reduce the risk of death or dependence on the modified Rankin Scale (grades 4 to 6) within 90 days of nontraumatic ICH (RR 0.79; 95% CI, 0.67 to 0.93) but not when assessed by the extended Glasgow Outcome Scale (RR 0.90; 95% CI, 0.81 to 1.01). A statistically significant excess of arterial thromboembolism at 160-μg/kg rFVIIa has been found in the trials (odds ratio 7.17, P=0.0004 versus placebo1).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Effect of hemostatic drugs compared with placebo or open control on death at 90 days of follow-up in patients with acute, nontraumatic intracerebral hemorrhage. ATICH was a trial of ε-aminocaproic acid

Implications for Clinical Practice

The evidence for the use of hemostatic drugs in the treatment of acute ICH is insufficient to provide clear guidelines for practice but should influence priorities for research.

Implications for Research

The clinical benefits of hemostatic drugs for acute nontraumatic ICH that have been observed among the secondary outcomes in phase II RCTs have led to a large phase III RCT of rFVIIa (FAST trial, NCT00127283). The FAST trial must (1) confirm or refute the apparent effects of rFVIIa on death or dependence and (2) provide more reliable evidence on whether any benefit from reduced hematoma growth is offset by an increase in arterial and venous thromboembolic events.

Evidence of the effects of less costly hemostatic drugs (for example, aprotinin, tranexamic acid, and ε-aminocaproic acid) in other clinical settings suggests that these drugs are also worth testing in large RCTs in people with acute nontraumatic ICH.

Note: The full text of this review is available in the Cochrane Library (for subscribers http://www.mrw.interscience.wiley. com/cochrane/clsysrev/articles/CD005951/frame.html). The full article should be cited as: You H, Al-Shahi R. Hemostatic drug therapies for acute primary intracerebral hemorrhage. Cochrane Database of Systematic Reviews. 2006, Issue 3. Art. No.: CD005951. DOI: 10.1002/14651858.CD005951.pub2.

Acknowledgments

We are grateful to Professor Christopher Ludlam (University of Edinburgh) and members of the Cochrane Stroke Review Group for their comments on the manuscript.

Sources of Funding

This review was funded by the China Scholarship Council and GanSu Province Peoples’ Hospital (to H.Y.) and a UK Medical Research Council Clinician Scientist Fellowship (to R.A.S.).

Disclosures

None.

  • Received September 3, 2006.
  • Accepted September 10, 2006.

References

  1. ↵
    Diringer MN, Selchen D, Davis S, Mayer SA, Brun NC, Broderick J, Skolnick BE, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Safety profile of recombinant factor VIIa in patients with intracerebral hemorrhage. Stroke. 2006; 37: 623. Abstract.
    OpenUrl
View Abstract

Jump to

  • Article
    • Objective
    • Search Strategy
    • Selection Criteria
    • Data Collection and Analysis
    • Main Results
    • Implications for Clinical Practice
    • Implications for Research
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Back to top
Previous ArticleNext Article

This Issue

Stroke
January 2007, Volume 38, Issue 1
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Objective
    • Search Strategy
    • Selection Criteria
    • Data Collection and Analysis
    • Main Results
    • Implications for Clinical Practice
    • Implications for Research
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Hemostatic Drug Therapies for Acute, Nontraumatic Intracerebral Hemorrhage
    Rustam Al-Shahi and Hong You
    Stroke. 2007;38:204-205, originally published December 22, 2006
    https://doi.org/10.1161/01.STR.0000251797.86897.a3

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Stroke.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Hemostatic Drug Therapies for Acute, Nontraumatic Intracerebral Hemorrhage
    (Your Name) has sent you a message from Stroke
    (Your Name) thought you would like to see the Stroke web site.
  • Share on Social Media
    Hemostatic Drug Therapies for Acute, Nontraumatic Intracerebral Hemorrhage
    Rustam Al-Shahi and Hong You
    Stroke. 2007;38:204-205, originally published December 22, 2006
    https://doi.org/10.1161/01.STR.0000251797.86897.a3
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Intervention, Surgery, Transplantation
    • Treatment
  • Critical Care and Resuscitation
    • Cardiopulmonary Resuscitation and Emergency Cardiac Care
  • Stroke
    • Intracranial Hemorrhage

Stroke

  • About Stroke
  • Instructions for Authors
  • Stroke CME
  • Guidelines and Statements
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 5th Avenue
Suite 1020
Waltham, MA 02451
email: stroke@strokeahajournal.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured